Inhibitors in nonsevere haemophilia A: outcome and eradication strategies
Inhibitors in nonsevere haemophilia A: outcome and eradication strategies
In nonsevere haemophilia A (HA) patients the presence of an inhibitor may exacerbate the bleeding phenotype dramatically. There are very limited data on the optimal therapeutic approach to eradicate inhibitors in these patients. We aimed to describe inhibitor eradication treatment in a large cohort of unselected nonsevere HA patients with inhibitors. We included 101 inhibitor patients from a source population of 2,709 nonsevere HA patients (factor VIII 2-40 IU/dl), treated in Europe and Australia (median age 37 years, interquartile range (IQR) 15-60; median peak titre 7 BU/ml, IQR 2-30). In the majority of the patients (71 %; 72/101) the inhibitor disappeared; either spontaneously (70 %, 51/73) or after eradication treatment (75 %, 21/28). Eradication treatment strategies varied widely, including both immune tolerance induction and immunosuppression. Sustained success (no inhibitor after rechallenge with factor VIII concentrate after inhibitor disappearance) was achieved in 64 % (30/47) of those patients rechallenged with FVIII concentrate. In high-titre inhibitor patients sustained success was associated with eradication treatment (unadjusted relative risk 2.3, 95 % confidence interval 1.3-4.3), compared to no eradication treatment. In conclusion, in nonsevere HA patients most inhibitors disappear spontaneously. However, in 35 % (25/72) of these patients an anamnestic response still can occur when rechallenged, thus disappearance in these patients does not always equal sustained response. Treatment for those requiring eradication has to be decided case by case, as one single approach is unlikely to be appropriate for all.
Adolescent, Adult, Antibodies/blood, Biomarkers/blood, Child, Child, Preschool, Desensitization, Immunologic/methods, Europe, Factor VIII/adverse effects, Hemophilia A/blood, Hemorrhage/blood, Hemostatics/adverse effects, Humans, Immune Tolerance, Immunosuppressive Agents/therapeutic use, Middle Aged, South Australia, Time Factors, Treatment Outcome, Young Adult
46-55
van Velzen, Alice S
f9520e65-1424-45ee-b3de-e493aba47ee3
Eckhardt, Corien L
0be27f57-141b-4d13-9e6a-e2a43593aaa0
Hart, Daniel P
806f3603-67f9-4f07-a8b7-9b183eb55c98
Peters, Marjolein
78454083-bc6b-4137-a2c5-c8a68ad1367b
Rangarajan, Savita
9a5e4c7e-55ba-4a3a-b5f6-f1e269d927c3
Mancuso, Maria Elisa
7e6a1556-52e5-4c1f-98f6-0655c38da1ab
Smiers, Frans J
dda42aa2-115c-4f6e-9d69-40fe8180a44a
Khair, Kate
8eed2e8f-c79b-4172-be6e-8755bf39e4cc
Petrini, Pia
ac409b2e-fb0e-4538-aba8-7de846104579
Jiménez-Yuste, Victor
bd63d57c-e8cd-4c9f-94b2-fc43170ff683
Hay, Charles R M
687ecb49-a7e6-4b56-8342-558d611af70e
van der Bom, Johanna G
b390e7a1-e4b0-40cd-84b2-bb8e2671dd92
Yee, Thynn T
a1e7ff43-fd54-4cf8-bded-78126fc587f4
Fijnvandraat, Karin
da8421df-054e-4f8c-ab51-a1f3bd247ffb
July 2015
van Velzen, Alice S
f9520e65-1424-45ee-b3de-e493aba47ee3
Eckhardt, Corien L
0be27f57-141b-4d13-9e6a-e2a43593aaa0
Hart, Daniel P
806f3603-67f9-4f07-a8b7-9b183eb55c98
Peters, Marjolein
78454083-bc6b-4137-a2c5-c8a68ad1367b
Rangarajan, Savita
9a5e4c7e-55ba-4a3a-b5f6-f1e269d927c3
Mancuso, Maria Elisa
7e6a1556-52e5-4c1f-98f6-0655c38da1ab
Smiers, Frans J
dda42aa2-115c-4f6e-9d69-40fe8180a44a
Khair, Kate
8eed2e8f-c79b-4172-be6e-8755bf39e4cc
Petrini, Pia
ac409b2e-fb0e-4538-aba8-7de846104579
Jiménez-Yuste, Victor
bd63d57c-e8cd-4c9f-94b2-fc43170ff683
Hay, Charles R M
687ecb49-a7e6-4b56-8342-558d611af70e
van der Bom, Johanna G
b390e7a1-e4b0-40cd-84b2-bb8e2671dd92
Yee, Thynn T
a1e7ff43-fd54-4cf8-bded-78126fc587f4
Fijnvandraat, Karin
da8421df-054e-4f8c-ab51-a1f3bd247ffb
van Velzen, Alice S, Eckhardt, Corien L, Hart, Daniel P, Peters, Marjolein, Rangarajan, Savita, Mancuso, Maria Elisa, Smiers, Frans J, Khair, Kate, Petrini, Pia, Jiménez-Yuste, Victor, Hay, Charles R M, van der Bom, Johanna G, Yee, Thynn T and Fijnvandraat, Karin
,
INSIGHT study group
(2015)
Inhibitors in nonsevere haemophilia A: outcome and eradication strategies.
Thrombosis and Haemostasis, 114 (1), .
(doi:10.1160/TH14-11-0940).
Abstract
In nonsevere haemophilia A (HA) patients the presence of an inhibitor may exacerbate the bleeding phenotype dramatically. There are very limited data on the optimal therapeutic approach to eradicate inhibitors in these patients. We aimed to describe inhibitor eradication treatment in a large cohort of unselected nonsevere HA patients with inhibitors. We included 101 inhibitor patients from a source population of 2,709 nonsevere HA patients (factor VIII 2-40 IU/dl), treated in Europe and Australia (median age 37 years, interquartile range (IQR) 15-60; median peak titre 7 BU/ml, IQR 2-30). In the majority of the patients (71 %; 72/101) the inhibitor disappeared; either spontaneously (70 %, 51/73) or after eradication treatment (75 %, 21/28). Eradication treatment strategies varied widely, including both immune tolerance induction and immunosuppression. Sustained success (no inhibitor after rechallenge with factor VIII concentrate after inhibitor disappearance) was achieved in 64 % (30/47) of those patients rechallenged with FVIII concentrate. In high-titre inhibitor patients sustained success was associated with eradication treatment (unadjusted relative risk 2.3, 95 % confidence interval 1.3-4.3), compared to no eradication treatment. In conclusion, in nonsevere HA patients most inhibitors disappear spontaneously. However, in 35 % (25/72) of these patients an anamnestic response still can occur when rechallenged, thus disappearance in these patients does not always equal sustained response. Treatment for those requiring eradication has to be decided case by case, as one single approach is unlikely to be appropriate for all.
This record has no associated files available for download.
More information
Accepted/In Press date: 13 February 2015
Published date: July 2015
Keywords:
Adolescent, Adult, Antibodies/blood, Biomarkers/blood, Child, Child, Preschool, Desensitization, Immunologic/methods, Europe, Factor VIII/adverse effects, Hemophilia A/blood, Hemorrhage/blood, Hemostatics/adverse effects, Humans, Immune Tolerance, Immunosuppressive Agents/therapeutic use, Middle Aged, South Australia, Time Factors, Treatment Outcome, Young Adult
Identifiers
Local EPrints ID: 443315
URI: http://eprints.soton.ac.uk/id/eprint/443315
ISSN: 0340-6245
PURE UUID: c9836d2c-f5f8-46b9-b0e1-fcd57cffab74
Catalogue record
Date deposited: 20 Aug 2020 16:33
Last modified: 17 Mar 2024 04:02
Export record
Altmetrics
Contributors
Author:
Alice S van Velzen
Author:
Corien L Eckhardt
Author:
Daniel P Hart
Author:
Marjolein Peters
Author:
Maria Elisa Mancuso
Author:
Frans J Smiers
Author:
Kate Khair
Author:
Pia Petrini
Author:
Victor Jiménez-Yuste
Author:
Charles R M Hay
Author:
Johanna G van der Bom
Author:
Thynn T Yee
Author:
Karin Fijnvandraat
Corporate Author: INSIGHT study group
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics